Fig. 3: Decline of hyperphosphorylated antigen precedes loss of seropositivity. | Nature Communications

Fig. 3: Decline of hyperphosphorylated antigen precedes loss of seropositivity.

From: Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms

Fig. 3: Decline of hyperphosphorylated antigen precedes loss of seropositivity.The alternative text for this image may have been generated using AI.

A Schematic overview of patients’ samples collected via a national pandemic multi-center network (NAPKON, validation cohort II) and included in long term follow-up analysis of autoantibody status. The logo in Fig. 3A was reused with permission from NAPKON. B,C Presence of hyper-phosphorylated PGRN (B, left panel) and IL-1Ra (C, left panel) as well as endogenous PGRN (B, right panel) and IL-1Ra (C, right panel) levels were determined by in-house (phospho-antigens) or commercial ELISA (endogenous PGRN and IL-1Ra) in baseline and follow-up samples collected within NAPKON. Data are shown as box and whiskers plots (min-max), including all individual data points, and data were analyzed by Kruskal-Wallis followed by Dunn’s multiple comparison test. (D, E) Paired analysis of total anti-PGRN IgG, hyperphosphorylated PGRN and PGRN plasma levels (D, left to right; baseline (BL) to 3-month follow up (3MFU): n = 62; 3MFU to 12-month follow up (12MFU: n = 36) and total anti-IL-1Ra IgG, hyperphosphorylated IL-1Ra and PGRN plasma levels (E, left to right; BL to 3MFU: n = 78; 3MFU to 12MFU: n = 50) in baseline and follow-up samples collected within NAPKON. Data are shown as aligned dot plots with lines connecting paired observations and were analyzed by a two-tailed Wilcoxon signed-rank test. F,G Anti-PGRN (F) and anti-IL-1Ra (G) antibody subclass distribution in baseline and follow-up samples collected within NAPKON.

Back to article page